Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05513014 · ClinicalTrials.gov registry record
Impact of Secukinumab on Clinical and Patient Reported Outcomes in Patients With Psoriasis
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 1,518
- Enrollment target
NCT05513014: Completed study, sponsored by Novartis Pharmaceuticals.
NCT05513014 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,518 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05513014 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 1,518 participants
- Enrollment target
Study Summary
The study was conducted to describe the demographics, disease characteristics, disease severity, comorbidities and patient reported outcomes at baseline and follow-up periods among adult patients diagnosed with PsO in CorEvitas' PsO Registry under routine medical care initiating secukinumab (SEC).
Primary Outcome
Age was reported to describe the sociodemographic characteristics of the patients.
Interventions
- DRUG Secukinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,518 participants |
| Start Date | 2021-03-21 |
| Est. Completion | 2021-08-31 |
What the finished NCT05513014 record still lists
NCT05513014 is an observational study that tracks outcomes without assigning an intervention. Its 1,518 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Secukinumab is the first listed.
NCT05513014 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05513014 about?
NCT05513014 is a clinical study titled "Impact of Secukinumab on Clinical and Patient Reported Outcomes in Patients With Psoriasis". The study was conducted to describe the demographics, disease characteristics, disease severity, comorbidities and patient reported outcomes at baseline and follow-up periods among adult patients diagnosed with PsO in CorEvitas' PsO Registry under routine medical care initiating secukinumab (SEC).
What is the current status of trial NCT05513014?
This trial is currently completed. The enrollment target is 1,518 participants. The study started on 2021-03-21. Estimated completion is 2021-08-31.
What interventions are being tested in trial NCT05513014?
The interventions under investigation include: Secukinumab (DRUG).
Who is sponsoring clinical trial NCT05513014?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07232017 · 1,520 participants
Implementation of Intensive Hypertension Management Approaches: Cleveland Clinic
- NCT05633654 · 1,514 participants · Phase 3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- NCT07136623 · 1,513 participants
Detecting Pulmonary Hypertension With the Eko CORE 500 Digital Stethoscope
- NCT06876714 · 1,524 participants · Phase 3
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI